Perimed

Perimed

Järfälla, Sweden· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Perimed is a long-established, privately-held developer of specialized medical instrumentation for vascular diagnostics and research. Its core technology platform is built around laser Doppler flowmetry and imaging, which enables non-invasive, real-time assessment of micro- and macrocirculation. The company's product lines, PeriFlux and PeriCam, are used globally in clinical and research settings to manage conditions like PAD and diabetic wounds, aiming to prevent amputations and improve patient outcomes. Perimed operates as a commercial-stage, revenue-generating entity, selling hardware and software systems directly to healthcare and research institutions.

Peripheral Artery DiseaseDiabetesWound CareVascular Surgery

Technology Platform

Core platform based on Laser Doppler Flowmetry (LDF) and Laser Speckle Contrast Imaging (LSCI) for non-invasive, real-time measurement and visualization of blood perfusion (microcirculation) and tissue oxygenation.

Opportunities

The global surge in diabetes and peripheral artery disease (PAD) creates a massive, growing addressable market for early diagnostic tools to prevent costly outcomes like amputations.
The shift towards value-based healthcare and postoperative monitoring in complex surgeries further drives demand for reliable, non-invasive perfusion measurement systems.

Risk Factors

Market adoption is constrained by variable reimbursement policies for vascular tests across different regions.
The company faces competition from alternative diagnostic technologies and larger medtech firms, and its growth is dependent on continuous innovation within its specialized technological niche.

Competitive Landscape

Perimed competes in the niche vascular diagnostics segment against other specialized firms offering laser Doppler, thermal imaging, and oximetry systems. It differentiates through its long heritage, dual-technology platform (LDF & LSCI), and focus on providing integrated 'multi-metric' assessments. Broader competition comes from large medtech companies with extensive vascular portfolios.